methyl 3-phenylpropyl carbonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-phenylpropyl carbonate
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: ALGTUOVZPBMCPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-phenylpropyl carbonate 生成 甲醇 、 烯丙苯
  参考文献：
  名称：

  气相中2-取代的乙基甲基碳酸酯的均相，非分子消除动力学中的机理和结构-反应性相关

  摘要：

  在静态反应系统中，在323–435°C的温度范围和28.5–242托的压力范围内，测定了2-取代的乙基碳酸甲酯的气相消除动力学。反应是均相的，单分子的并且遵循一阶速率定律。报道了动力学和热力学参数。使用塔夫脱-托普索姆法时，碳酸甲乙酯的2个取代基（CH 3 OCOOCH 2 CH 2 Z，Z =取代基）呈现近似线性相关，log（k Z / k H）=-（0.57±0.19）σ α +（1.34±0.49）σ - [R -（ - [R= 0.9256；SD = 0.16）在400°C下。该结果暗示消除过程对空间因素敏感，而电子效应并不重要。然而，该共振系数具有用于C的β氢的有利抽象影响最大β由氧羰基-H键。因为ρ α是显著，获得具有Hancock的立体参数碳酸酯的烷基取代基的一个良好的相关性：日志（ķ - [R / ķ ħ）与Ë小号Ç为CH 3 OCOOCH 2 CH 2 - [R在400℃下，R

  DOI：

  10.1002/poc.665
• 作为产物：
  描述：

  cinnamyl methyl carbonate 在 [(COD)Ir(PMe₂Ph)(IMes)]BArF 、 氢气 作用下， 以 二氯甲烷 为溶剂， -78.0~25.0 ℃ 、101.33 kPa 条件下， 反应 2.0h， 以97%的产率得到methyl 3-phenylpropyl carbonate
  参考文献：
  名称：

  铱（I）N-杂环卡宾（NHC）/膦催化剂用于轻度和化学选择性加氢工艺

  摘要：

  已经通过使用铱（I）催化剂建立了烯烃的定向化学选择性加氢，该催化剂具有可调节的NHC /膦配体组合。该选择性还原过程已在多种溶剂（包括更环境可接受的介质）中得到证明，还允许进一步提高氢化选择性。

  DOI：

  10.1002/chem.201504825

文献信息

• Unique catalysis of gold nanoparticles in the chemoselective hydrogenolysis with H2: cooperative effect between small gold nanoparticles and a basic support
  作者：Akifumi Noujima、Takato Mitsudome、Tomoo Mizugaki、Koichiro Jitsukawa、Kiyotomi Kaneda

  DOI：10.1039/c2cc32850j

  日期：——

  Gold nanoparticles on hydrotalcite act as a heterogeneous catalyst for the chemoselective hydrogenolysis of various allylic carbonates to the corresponding terminal alkenes using H2 as a clean reductant. The combination of gold nanoparticles and basic supports elicited significantly unique and selective catalysis in the hydrogenolysis.

  金纳米颗粒在水滑石上作为异质催化剂，用于选择性氢解各种烯丙基碳酸盐，生成相应的末端烯烃，以H2作为清洁还原剂。金纳米颗粒与碱性载体的结合显著引发了独特的选择性氢解催化作用。
• MANUFACTURING METHOD OF ORGANOBORON COMPOUND
  申请人：SAWAMURA Masaya

  公开号：US20080262257A1

  公开（公告）日：2008-10-23

  A manufacturing method for one of, or a mixture of, an optically active allylboron compound and racemic or optically active boryl cyclopropane, including a coupling reaction, in the presence of a catalyst, between allyl compound and diboron compound. It is preferred that a copper (I) complex is used as the catalyst. It is preferred that a counterion of the copper (I) complex is an alkoxide or a hydride. It is preferred that the copper (I) complex has a phosphine ligand. It is preferred that the phosphine ligand is a chiral phosphine ligand.

  一种制备手性烯丙基硼化合物和外消旋或手性的硼代环丙烷混合物的方法，包括在催化剂存在下，烯丙基化合物和二硼化合物之间的偶联反应。最好使用铜(I)配合物作为催化剂。最好铜(I)配合物的反离子是醇盐或氢化物。最好铜(I)配合物具有膦配体。最好膦配体是手性膦配体。
• [EN] COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE<br/>[FR] PROMÉDICAMENTS DE LIBÉRATION DE CYCLISATION D'ESTER DE NÉOPENTYLE SULFONYLE D'ESTER D'ACIDE PANTOÏQUE COMPLEXE D'ACAMPROSATE, LEURS COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：XENOPORT INC

  公开号：WO2009033054A1

  公开（公告）日：2009-03-12

  Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate of formula (I), pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorders, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis and pain are disclosed.

  本发明涉及公式（I）的戊二酸酯新戊基磺酰酯前药，包括这种前药的制药组合物，以及使用这种前药和组合物治疗疾病的方法。具体而言，本发明揭示了具有增强口服生物利用度的戊二酸酯前药，并使用这些前药治疗神经退行性疾病、精神疾病、情绪障碍、焦虑症、躯体形式障碍、运动障碍、物质滥用障碍、暴食障碍、皮层扩散性抑制相关障碍、耳鸣、睡眠障碍、多发性硬化和疼痛等疾病的方法。
• COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Jandeleit Bernd

  公开号：US20090076147A1

  公开（公告）日：2009-03-19

  Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

  本文公开了帕托酸酯新戊磺酰酯丙戊酸酯前药、包含这种前药的制药组合物以及使用这种前药和组合物治疗疾病的方法。具体而言，本文公开了增强口服生物利用度的丙戊酸酯前药，并公开了使用丙戊酸酯前药治疗神经退行性疾病、精神疾病、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴食症、皮层扩散性抑制相关障碍、耳鸣、睡眠障碍、多发性硬化和疼痛的方法。
• Easy eco-friendly phenonium ion production from phenethyl alcohols in dimethyl carbonate
  作者：M. Barontini、I. Proietti Silvestri、V. Nardi、P. Bovicelli、L. Pari、F. Gallucci、R. Spezia、G. Righi

  DOI：10.1016/j.tetlet.2013.06.122

  日期：2013.9

  An efficient and simple one-pot procedure for selective etherification of 2-aryl-ethylalcohols has been achieved through Amberlyst 15-catalyzed reaction in dimethyl carbonate (DMC). Moreover, the polymer catalyst could be recovered and reused with no effect on its activity. The reaction mechanism involves the formation of phenonium ion which has been demonstrated by a C-C bond forming reaction. Theoretical studies are in agreement with and thus explain experimental results. (C) 2013 Elsevier Ltd. All rights reserved.